Related MeSH Hierarchy (4)
Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » alpha 1-Antitrypsin Deficiency
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » alpha 1-Antitrypsin Deficiency
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » alpha 1-Antitrypsin Deficiency
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Emphysema » Subcutaneous Emphysema » alpha 1-Antitrypsin Deficiency
Description
Deficiency of the protease inhibitor ALPHA 1-ANTITRYPSIN that manifests primarily as PULMONARY EMPHYSEMA and LIVER CIRRHOSIS. MeSH
Hierarchy View
Approved Indicated Drugs (1)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (30)
Icahn School of Medicine at Mount Sinai
Medical University of South Carolina
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.